Navigation Links
Proteomic profiling shown more accurate than traditional biomarkers in identifying liver cancer
Date:1/14/2008

BOSTON As the incidence of liver cancer continues to grow-- fueled in large part, by rising rates of hepatitis C infections so too does the need for tests to help diagnose the disease at an earlier stage. A study appearing in the January 15 issue of Clinical Cancer Research demonstrates that a novel mass-spectrometry based form of proteomic profiling is more accurate than traditional biomarkers in distinguishing liver cancer patients from patients with hepatitis C liver cirrhosis, particularly with regard to identifying patients with small, curable tumors. Led by researchers at Beth Israel Deaconess Medical Center (BIDMC), the study could help lead to earlier diagnostic methods and subsequent treatments -- for liver cancer.

Proteomics represents a potentially powerful tool for the serologic recognition of protein profiles associated with cancer, explains co-senior author Towia Libermann, PhD, Director of the Genomics Center at BIDMC and Associate Professor of Medicine at Harvard Medical School.

Although this particular proteomics technology, SELDI-TOF MS [surface enhanced laser desorption/ionization time of flight mass spectrometry] had already proven capable of identifying liver cancer in some limited studies, this was the first time that the technology was compared side-by-side with the clinical standard biomarker in a cohort of patients at risk for developing the disease, adds Liebermann, who is also Director of the Dana-Farber/Harvard Cancer Center Proteomics Core in the Division of Interdisciplinary Medicine and Biotechnology at BIDMC.

Over a single decade, the incidence of liver cancer (hepatocellular carcinoma) increased from 1.8 to 2.5 per 100,000 patients, in large part due to a rise in the spread of hepatitis C virus.

Hepatitis C has become a tremendous public health problem, explains co-senior author Nezam Afdhal, MD, Director of the Liver Center at BIDMC and Associate Professor of Medicine at Harvard Medical School. And a significant number of hepatitis C-infected patients will go on to develop liver cirrhosis. Cirrhosis results when healthy tissue is replaced by scar tissue, preventing the liver from properly functioning. Cirrhosis itself is responsible for more than 25,000 deaths each year. But, adds Afdhal, secondarily, cirrhosis greatly increases a persons chances of developing liver cancer.

Each year, cirrhosis patients have a two to five percent chance that their condition will escalate to cancer, he explains. And the problem is that, right now, there is no reliable means of detecting liver cancer at an early stage, when surgical treatment is an option. Typically by the time the disease is discovered, the cancer has advanced and treatment options become much more limited.

The best hope for early detection is cancer biomarkers, serum proteins found in altered amounts in blood or other body fluids. The current biomarker for liver cancer in clinical use is alpha fetoprotein (AFP). In many cases, patients with hepatitis C undergo routine monitoring for AFP levels as an indicator of whether tumors may have developed in their livers.

But, as Libermann explains, the AFP biomarker has a number of shortcomings, including false positives and false negatives. AFP not only fails to detect many early tumors, but it also lacks specificity. Consequently, elevated AFP levels could be indicators of not only cancer, but also of other liver diseases or even benign conditions, while on the other hand, many patients with small tumors will test negative for AFP.

The authors, therefore, decided to evaluate the sensitivy and specificity of SELDI-TOF MS for the detection of liver cancer and to compare its effectiveness with AFP.

Examining serum samples of 92 patients including 51 patients with liver cirrhosis and 41 patients with liver cancer, and among the cancer patients, individuals with both large and small (less than 2 cm) tumors -- by SELDI-TOF mass spectrometry, the investigators were able to identify an 11-protein signature that accurately discriminated between the cirrhosis and cancer patients, first in a training set (made up of 26 cirrhosis and 20 liver cancer patients), and then again in an independent validation set (consisting of 25 cirrhosis and 19 liver cancer patients). The resulting diagnostic value 74 percent sensitivity and 88 percent specificity compared favorably with the diagnostic accuracy of AFP (73 percent sensitivity and 71 percent specificity) as well as with two other biomarkers currently in clinical development for liver cancer, AFP-L3 and PIVKA-IL.

Most strikingly, notes Libermann, in patients with small tumors (less than 2 cm), where AFP identified only three, and AFP-L3 and PIVKA-II only one each, the 11-protein signature correctly identified seven of eight patients at this early stage of disease.

Biomarkers play a major role in all aspects of personalized medicine, not only in early disease detection, but also in outcome prediction and evaluation of therapeutic responses, he adds. This study provides strong evidence that serum contains early detection biomarkers and supports the notion that a combination of multiple biomarkers may prove more effective than individual biomarkers for diagnosis of liver cancer, as well as other cancers.


'/>"/>

Contact: Bonnie Prescott
bprescot@bidmc.harvard.edu
617-667-7306
Beth Israel Deaconess Medical Center
Source:Eurekalert

Related medicine news :

1. Story ideas from molecular & cellular proteomics
2. Genomic profiling of lung tumors helps doctors choose most effective treatment
3. Molecular profiling can accurately predict survival in colon cancer patients
4. Gene profiling can single out the worst cases of multiple myeloma and guide therapy
5. Mayo Clinic to Pilot Collexis Expert Profiling
6. MammaPrint(R) Breast Cancer Test Shown To Be Powerful Tool for Prognosis Prediction in Postmenopausal Breast Cancer Patients
7. Once-Daily Exjade(R) Shown to Remove Toxic Iron From the Heart and Liver, According to Data Presented at ASH
8. Wild Blueberries Shown to Fight Oxidative Stress
9. Video game shown to cut cortisol
10. Breaking Study: Masimo Pleth Variability Index (PVI) Shown Effective in Noninvasive Detection of Changes in Ventricular Preload and Fluid Volume
11. Drug Detection Kits Manufactured By IDenta Corp. Shown During French Television Broadcast (at TF1) - Product Aids French Police In Bust of 600 Kilograms Of Cocaine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... 2017 , ... “Code Word: Chocolate Biscuit”: a biographical account following a man who went on ... of published author, Marlyn Ivey, born in Lynn Haven, Florida and at the age of ... 19 years of age, he joined the Navy and got married right out of boot ...
(Date:1/20/2017)... ... 20, 2017 , ... D R Burton Healthcare Products LLC, ... featured in a study indicating superior performance against competitive products in secretion clearance. ... Oscillating Positive Expiratory Pressure Devices During Simulated Breathing“ was published in the winter ...
(Date:1/20/2017)... ... ... enchanting tale that teaches children the true meaning of Christmas. “Journey to Christmas” is the ... devoted woman of faith. , “Becoming a parent changes you. In my case, the ... years, but actually doing it might have been a while in coming if it hadn’t ...
(Date:1/20/2017)... ... , ... “The Land of More and More”: a brilliant story for ... shares the simple and achievable answer. “The Land of More and More” is the ... Church in Angola, Indiana where he works with the children’s ministry department. , ...
(Date:1/19/2017)... ... 2017 , ... Today, the Centers for Medicare & Medicaid Services (CMS) announced ... Models (APMs) in 2017. Clinicians who participate in APMs are paid for the quality ... the Administration’s effort to build a system that delivers better care and one in ...
Breaking Medicine News(10 mins):
(Date:1/20/2017)... Research and Markets has announced the addition of the ... Amplifiers, Diagnostic Instruments), Sales Volume, Company Analysis and Forecast to ... ... Volume, Company Analysis and Forecast to 2022 provides a comprehensive ... The growing prevalence of hearing impairment coupled with an expanding ...
(Date:1/20/2017)... , Jan. 20, 2017  Palladian Health, ... has announced the launch of an opioid management ... guidelines on opioids and helps stem the growing ... often prescribed to treat chronic non-cancer pain (back ... serious risks and lack of evidence regarding long-term ...
(Date:1/19/2017)... 2017 Germany Cataract Surgery ... new report, "Germany Cataract Surgery Devices Market Outlook to ... Surgery Devices market. The report provides value, in millions ... (USD) within market segements - Phacoemulsification Equipment and Ophthalmic ... shares and distribution shares data for each of these ...
Breaking Medicine Technology: